Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 18/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 18/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 18/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 14/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645784 | 0.93 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644516 | 0.92 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644499 | 0.86 | GABRG2 (0.59) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2651943 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652390 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644651 | 0.82 | GABRG2 (0.71) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644140 | 0.81 | GABRG2 (0.58) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2646012 | 0.80 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2645228 | 0.79 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2645333 | 0.78 | ALDH1A1 (0.63) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | claimed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | claimed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | GABRG2 15/4885GABRB3 10/4885GABRA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.